Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. - Investor Relations & Filings

Listed IPO Jul 1975
Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2025-03-19 Audit Report / Informat…
Country KR South Korea
Listing KO 001360 · 1 venue

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Samsung Pharmaceutical Co., Ltd. for the fiscal year ending December 31, 2024. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. While it contains financial data, it is specifically the formal audit report required by regulatory standards, distinct from a 10-K (which is a broader annual report) or a simple earnings release. Therefore, it is classified as an Audit Report. FY 2024
2025-03-19 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Samsung Pharmaceutical. It outlines the date, location, and agenda items (financial statements, director appointments, and remuneration limits). This document serves as the official notification and proxy-related information for an upcoming shareholder meeting, which falls under the category of Proxy Solicitation & Information Statement.
2025-03-12 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Samsung Pharmaceutical Co., Ltd. It contains the meeting agenda, date, location, and detailed information regarding the items to be voted on, such as financial statement approval and director appointments. It also includes supplementary information like board activity reports and financial statements, which are standard components of proxy materials sent to shareholders to solicit votes for an AGM. This fits the definition of a Proxy Solicitation & Information Statement.
2025-03-12 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (DART system) used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains the agenda, director candidate information, and financial statements for the meeting. This falls under the category of Proxy Solicitation & Information Statement.
2025-03-12 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date'. It explains the company's inability to avoid the concentrated date due to audit and closing schedules. Since this is a regulatory disclosure regarding meeting logistics and compliance with the 'Shareholder Meeting Dispersion Voluntary Compliance Program' rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2025-03-12 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from Samsung Pharmaceutical regarding a significant change (30% or more) in sales or profit/loss structure. It provides preliminary financial data (revenue, operating profit, net income) for the current fiscal year compared to the previous year. This type of disclosure is a standard regulatory requirement in the Korean market (KRX) for listed companies to announce material financial changes before the final audit report is filed. It fits the 'Earnings Release' (ER) category as it provides the initial announcement of financial results highlights. FY 2024
2025-02-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.